Although numerous protein therapeutics have been approved or are in advanced clinical
testing, the development of more sophisticated delivery systems for this rapidly expanding …

Over the past decade developments in the field of biotechnology have led to the cloning,
characterization, and commercial availability of many clinically useful proteins and peptides …

Chemotherapy for brain tumours has been limited because of difficulty in achieving
adequate exposure to the tumour without systemic toxicity. We have developed a method for …

Written at a level comprehensible to non-experts, this handbook covers the current state of
encapsulation and controlled released technologies, presenting the fundamental processes …

Synthetic materials are a tremendous potential resource for treating human disease. For the
rational design of many of these biomaterials it is necessary to have an understanding of …

DURING the last glaciation, the atmospheric carbon dioxide concentration was about 30%
less than the Holocene pre-industrial value1. Although this change is thought to originate in …

✓ Malignant gliomas have been difficult to treat with chemotherapy. The most effective
agent, BCNU (carmustine), has considerable systemic toxicity and a short half-life in serum …

3.1. 2. Gelatin 3.1. 3. Other proteins 3.2. Synthetic polypeptides 3.2. 1. Water-soluble
synthetic polypeptides 3.2. 2. Synthetic polypeptide hydrogels 3.2. 3. Synthetic polypeptide …

The design and development of tissue-engineered products has benefited from many years
of clinical utilization of a wide range of biodegradable polymers. Newly developed …

Particles with liquid cores and solid shells have been prepared by the controlled phase
separation of poly (methylmethacrylate)(PMMA) within the droplets of an oil-in-water …